You can’t turn around without hearing the S&P 500 printed 2,000, again, making another record. Can stocks possibly go higher?» Read More
Stock and options traders are piling into Biogen Idec on speculation that the drug maker could be a takeover target. About 75,000 options contracts traded on the name, more than 10 times the average over the last 20 session...
Cramer makes the call on viewers' favorite stocks.
The cola wars are coming to an end, and Cramer has chosen a winner.
Following are the week’s biggest winners and losers. Find out why shares of AK Steel and Wynn Resorts popped while Monsanto and Capital One dropped..
"This is a really big moment," says one investment pro. "The real question in my mind is if we are dragging the floor up."
The markets surged on Wednesday following the Fed's announcement that it would buy up to $300 billion in longer-term debt. At the session high shortly after the Fed's announcement, the S&P 500 climbed back above the 800 level for the first time since February 17. The index, however, still hasn't closed above 800 since February 13. Nevertheless, by crossing the 800 mark during the day yesterday, the S&P had officially moved up over 20% from its March 6 low of 666.79.
The stock market's surprising show of strength Tuesday is convincing traders the rally still has a ways to go.
Here's our Fast Money Final Trade. Our gang gives you tomorrow's best trades, right now!
The abrupt end of Wall Street's latest rally proves once again that short-term investing is a hazardous business, according to Sarat Sethi of Douglas C. Lane & Associates. That having been said, there are more short-term opportunities coming.
In an era that some might call corporate welfare, Cramer discusses who needs to generate their own cash.
Last week was a busy week, to say the least, on the Pharma beat - So I was looking forward to the weekend and escaping all things drug-related. But as fate would have it, it ended up being bookended by references to pharma in a couple of surprising venues.
In today’s Fast Money final call, with big deals being made in big Pharma, is this a one-sector phenomenon? Pete Najarian, co-founder of OptionMonster.com, doesn’t think so.
Retailers, fast food restaurants and consumer goods manufacturers are seeing a strong response as frugal consumers try to weather the economic downtown.
Even better: Events that could push the Dow up another 1,000 points.
The IBB biotech ETF is drawing strong options activity Thursday, as news ranging from mergers to government regulation continues to rock the sector.
The Biotechnology Industry Organization just announced that Sir Elton will be the keynote speaker at the 2009 BIO International Convention in Atlanta, the superstar's American hometown.
With cash scarce, credit tight and big drug companies intent on branching into biotechnology themselves, struggling bio-tech start-ups may no longer get second and third chances to succeed from thier investors, the New York Times reports.
The final form of health-care reform is hardly clear, but Joel Sendek of Lazard Capital Markets says he's heard enough to point him toward some rewarding stock-market investments.
Amid the gloom, Birinyi Associates' Cleve Rueckert found what he sees as a bright spot in the stock market. In a note, he says growth is the place to be, based on performance of the S&P's Pure Growth Index versus the S&P Pure Value Index. Here's his list of 15 stocks in the S&P 500 that fit three key growth criteria.
Even though nearly every analyst this morning is saying Thursday's bloodbath was an overreaction, investors are continuing to sell biopharma stocks in the early going Friday.